News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Two Grants Totaling EUR 1.65 Million by the German Federal Ministry of Education and Research (BMBF) to Support Apogenix´ Research


9/22/2008 3:30:05 PM

HEIDELBERG, Germany, Sept. 19, 2008 - Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced the granting of additional research funding amounting to EUR 1.65 million. The two grants were awarded by the German Federal Ministry of Education and Research (BMBF) in the context of Germany´s renowned programs “BioChancePlus” and “Innovative Molecular and Cellular-Based Therapies”.

Read at PharmaLive

comments powered by Disqus
Apogenix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES